XML 35 R16.htm IDEA: XBRL DOCUMENT v3.26.1
Supplemental Financial Information
12 Months Ended
Dec. 31, 2025
Balance Sheet Related Disclosures [Abstract]  
Supplemental Financial Information

Note 4—Supplemental Financial Information

Property, plant and equipment, net consisted of the following (in thousands):

 

 

December 31,
2025

 

 

December 31,
2024

 

Leasehold improvements

 

$

2,152

 

 

$

2,117

 

Laboratory equipment

 

 

3,306

 

 

 

3,130

 

Computer equipment

 

 

749

 

 

 

707

 

Furniture and fixtures

 

 

921

 

 

 

864

 

Construction in progress

 

 

4,292

 

 

 

4,251

 

 

 

11,420

 

 

 

11,069

 

Accumulated depreciation

 

 

(4,684

)

 

 

(3,584

)

Property, plant and equipment, net

 

$

6,736

 

 

$

7,485

 

Property, plant and equipment, net includes $0.3 million and $0.7 million of assets capitalized as finance leases as of December 31, 2025 and December 31, 2024, respectively. During the year ended December 31, 2025, the Company sold equipment with a book value of zero and recorded a gain on the disposal of $0.1 million.

Depreciation expense was $1.1 million and $1.2 million for the years ended December 31, 2025 and 2024, respectively.

In September 2024, the Company recorded an impairment loss of $4.8 million in connection with its North Carolina manufacturing facility. The impairment charge was estimated using a discounted cash flow model and recorded in the consolidated statements of operations for the year ended December 31, 2024.

Accrued expenses and other current liabilities consisted of the following (in thousands):

 

 

December 31,
2025

 

 

December 31,
2024

 

Accrued compensation

 

$

9,425

 

 

$

5,242

 

Accrued research and development

 

 

3,591

 

 

 

1,714

 

Accrued clinical trial

 

 

3,290

 

 

 

1,907

 

Lease liabilities, current portion

 

 

1,865

 

 

 

1,877

 

Warrant liability

 

 

 

 

 

438

 

Accrued professional and consulting fees

 

 

1,310

 

 

 

725

 

Accrued property, plant and equipment

 

 

19

 

 

 

207

 

Other

 

 

777

 

 

 

752

 

Total accrued expenses and other current liabilities

 

$

20,277

 

 

$

12,862

 

Prepaid expenses and other current assets consisted of the following (in thousands):

 

 

December 31,
2025

 

 

December 31, 2024

 

Prepaid research and development

 

$

2,460

 

 

$

841

 

Prepaid clinical trial

 

 

866

 

 

 

1,112

 

Deferred offering costs

 

 

195

 

 

 

135

 

Prepaid insurance

 

 

108

 

 

 

249

 

Other

 

 

802

 

 

 

308

 

Total prepaid expenses and other current assets

 

$

4,431

 

 

$

2,645